Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Immunovant Inc. (IMVT)

NASDAQ: IMVT · Biological Products, (No Diagnostic Substances) · Durham, NC

Our rating: Neutral

Call changed from Cautious to Neutral at $35.71, moderate conviction, November 10, 2026.

Breaks if: The Neutral call moves Cautious if the stock falls 35% or more from the current $35.71 within twelve months — a decline of that magnitude at this market cap would almost certainly reflect a pivotal-trial failure or a financing event signaling the runway is narrower than assumed, either of which would change the fundamental picture. It moves Positive if the stock clears and holds above $56 — roughly 57% above today — on the back of a material clinical or regulatory catalyst, at which point the market will have done the work of pricing a credible commercial inflection and the question shifts to durability rather than existence.

Key figures

Market value$6.6B
Revenue, last 12 monthsn/a
Net income, last 12 months−$509M
Free cash flow, last 12 monthsn/a
Price to earningsn/a
Free cash flow yieldn/a
Dividend yield0.0%
Operating marginn/a
Return on equity−86.5%
Beta to the S&P 5001.23
Volatility, annualized55.8%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026n/an/a$-0.47n/a
June 30, 2026n/an/a$-0.75n/a
March 31, 2026n/an/a$-0.73−$95M
December 31, 2025n/an/a$-0.61−$92M
September 30, 2025n/an/a$-0.73−$103M
June 30, 2025n/an/a$-0.71−$117M
March 31, 2025n/an/a$-0.63−$111M
December 31, 2024n/an/a$-0.76−$101M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

14 ledger entries and 19 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.